Middle East Healthcare Future Growth
Future criteria checks 3/6
Middle East Healthcare is forecast to grow earnings and revenue by 17.9% and 9.6% per annum respectively. EPS is expected to grow by 17.9% per annum. Return on equity is forecast to be 17.7% in 3 years.
Key information
17.9%
Earnings growth rate
17.9%
EPS growth rate
| Healthcare earnings growth | 14.7% |
| Revenue growth rate | 9.6% |
| Future return on equity | 17.7% |
| Analyst coverage | Low |
| Last updated | 05 Feb 2025 |
Recent future growth updates
Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09
Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09Recent updates
With EPS Growth And More, Middle East Healthcare (TADAWUL:4009) Makes An Interesting Case
Dec 16Investors Will Want Middle East Healthcare's (TADAWUL:4009) Growth In ROCE To Persist
Sep 24Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings
Jul 18There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital
May 30Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity
Apr 29Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge
Apr 02There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump
Feb 11Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled
Feb 08Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?
Jan 18Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors
Dec 28Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends
Sep 26Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Jun 28Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Mar 30Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal
Sep 20Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)
Jun 14Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture
Apr 18Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Aug 10Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends
Mar 29An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued
Mar 03Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 10Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock
Jan 23If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%
Jan 05Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?
Dec 18Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)
Nov 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 4,011 | 410 | 525 | 692 | 2 |
| 12/31/2026 | 3,634 | 346 | 228 | 469 | 3 |
| 12/31/2025 | 3,250 | 303 | 120 | 470 | 3 |
| 12/31/2024 | 2,921 | 239 | 181 | 652 | 2 |
| 9/30/2024 | 2,854 | 211 | 203 | 665 | N/A |
| 6/30/2024 | 2,793 | 203 | -23 | 196 | N/A |
| 3/31/2024 | 2,704 | 182 | 69 | 270 | N/A |
| 12/31/2023 | 2,653 | 180 | -41 | 191 | N/A |
| 9/30/2023 | 2,551 | 177 | 23 | 282 | N/A |
| 6/30/2023 | 2,393 | 135 | 63 | 346 | N/A |
| 3/31/2023 | 2,276 | 105 | -95 | 172 | N/A |
| 12/31/2022 | 2,152 | 75 | -174 | 76 | N/A |
| 9/30/2022 | 2,033 | 24 | -292 | 9 | N/A |
| 6/30/2022 | 2,019 | 27 | -309 | 1 | N/A |
| 3/31/2022 | 1,968 | 26 | -259 | 114 | N/A |
| 12/31/2021 | 1,873 | 17 | -341 | 77 | N/A |
| 9/30/2021 | 1,823 | 45 | -434 | -37 | N/A |
| 6/30/2021 | 1,816 | 66 | -580 | -160 | N/A |
| 3/31/2021 | 1,733 | 73 | -501 | -166 | N/A |
| 12/31/2020 | 1,751 | 82 | -524 | -229 | N/A |
| 9/30/2020 | 1,708 | 110 | -507 | -182 | N/A |
| 6/30/2020 | 1,603 | 108 | -348 | -23 | N/A |
| 3/31/2020 | 1,583 | 104 | -440 | -38 | N/A |
| 12/31/2019 | 1,497 | 98 | -373 | 99 | N/A |
| 9/30/2019 | 1,401 | 91 | -351 | 133 | N/A |
| 6/30/2019 | 1,353 | 78 | -335 | 180 | N/A |
| 3/31/2019 | 1,346 | 100 | -289 | 164 | N/A |
| 12/31/2018 | 1,391 | 172 | -197 | 159 | N/A |
| 9/30/2018 | 1,445 | 224 | -39 | 317 | N/A |
| 6/30/2018 | 1,459 | 269 | N/A | 204 | N/A |
| 3/31/2018 | 1,464 | 297 | N/A | 135 | N/A |
| 12/31/2017 | 1,462 | 319 | N/A | 347 | N/A |
| 9/30/2017 | 1,503 | 322 | N/A | 370 | N/A |
| 6/30/2017 | 1,529 | 356 | N/A | 256 | N/A |
| 3/31/2017 | 1,588 | 368 | N/A | 453 | N/A |
| 12/31/2016 | 1,616 | 363 | N/A | 253 | N/A |
| 9/30/2016 | 1,629 | 380 | N/A | 72 | N/A |
| 6/30/2016 | 1,602 | 371 | N/A | 313 | N/A |
| 3/31/2016 | 1,564 | 389 | N/A | 303 | N/A |
| 12/31/2015 | 1,535 | 390 | N/A | 194 | N/A |
| 9/30/2015 | 1,485 | 373 | N/A | 434 | N/A |
| 6/30/2015 | 1,456 | 356 | N/A | 383 | N/A |
| 3/31/2015 | 1,431 | 357 | N/A | 253 | N/A |
| 12/31/2014 | 1,399 | 332 | N/A | 349 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4009's forecast earnings growth (17.9% per year) is above the savings rate (14.9%).
Earnings vs Market: 4009's earnings (17.9% per year) are forecast to grow faster than the SA market (5.9% per year).
High Growth Earnings: 4009's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4009's revenue (9.6% per year) is forecast to grow faster than the SA market (-0.6% per year).
High Growth Revenue: 4009's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4009's Return on Equity is forecast to be low in 3 years time (17.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 11:44 |
| End of Day Share Price | 2025/02/13 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Middle East Healthcare Company is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jassim Al-Jubran | Aljazira Capital Company |
| Madhu Appissa | Al Rajhi Capital |
| Christine Kalindjian | Arqaam Capital Research Offshore S.A.L. |